VJHemOnc is committed to improving our service to you

ASH 2019 | Outcomes in RRMM treated with IRd in the real world

VJHemOnc is committed to improving our service to you

Faith Davies

Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, discusses an expanded pooled analysis with longer follow-up of ixazomib-lenalidomide-dexamethasone (IRd) therapy from the INSIGHT MM study (NCT02761187) and the Czech Registry of Monoclonal Gammopathies (RMG) to evaluate the effectiveness of IRd in relapsed/refractory multiple myeloma (MM) patients in routine clinical practice. The findings suggest outcomes in patients treated with IRd in the real world remain comparable to the outcomes reported in the phase 3 TOURMALINE-MM1 study (NCT01564537). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter